Brian Leyland-Jones BSc (1st Class Hons), MB BS, LRCP, MRCS, ECFMG, PhD, FACP, FRCPC
Dr. Leyland-Jones is a past Chief of Developmental Therapeutics at the National Cancer Institute (NCI) and has served as principal, co-principal, and co-investigator on more than 100 clinical studies. While at the NCI. he coordinated the international development of Paclitaxel, and while at McGill, made numerous contributions to the development of Herceptin, including the design of 0648G (metastatic approval), the design of HERA, the design of NeoSphere and he pioneered the 3-weekly schedule.
He has authored and co-authored more than 246 peer reviewed articles and book contributions, 25 books and book chapters, 427 abstracts and 35 patents. He is the recipient of numerous prestigious awards and honors, including being presented with the 2021 McGill University Lifetime Achievement award as well as being awarded the Cheadle Gold Medal at graduation. He is a recipient of grants from the NCI (P30), NCIC, DOD Breast Cancer Center of Excellence Award and FDA (Orphan). Dr. Leyland-Jones is also a recipient of PMA Clinical Fellow and Faculty Awards and was a 2007 Georgia Research Alliance, Eminent Scholar and a Georgia Cancer Coalition, Distinguished Cancer Scholar.
Dr. Leyland-Jones has served as the director of two major cancer centers, holding positions as the Founding Chair of Oncology and Director of the McGill University Comprehensive Cancer Center (Minda de Gunzberg Chair); Director of the Winship Cancer Centre and Associate Vice President of Health Science at Emory University (first director to achieve NCI designation in 30 years). He was also a Visiting Professor at Stanford University and also served as Vice President of the Molecular and Experimental Genomics Medicine Program at the Avera Cancer Institute.
He holds biochemistry, medical and doctoral degrees from the University of London. Dr. Leyland-Jones completed residency training at London hospitals including St. Mary’s, Hammersmith, Brompton, St. Bartholomew’s and the London Hospital. He completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center.
He is a Harvard alumnus (HBS Managing Health Care Delivery, Preparing to be a Corporate Director- Board Governance and PLD35)
He has founded or co-founded several companies including Xanthus Pharmaceuticals Ltd (exit to Antisoma), AKESOgen Inc. (exit to Tempus), Viviphi, Parthen and PITO.
Dr. Leyland-Jones is an Emeritus Board Member for the WIN Consortium. He currently serves as Chief Medical Officer, Board Member and Treasurer of the National Foundation for Cancer Research (NFCR), Scientific Advisory Board Member for the Asian Foundation for Cancer Research (AFCR) and Vice-Chair of AIM-HI.
